Perspective Therapeutics

Perspective Therapeutics appointed biotech veteran Joel Sendek as Chief Financial Officer, bringing extensive experience from four previous CFO roles and over $2.5 billion in fundraising expertise.

Perspective Therapeutics has dosed the first patient with [212Pb]PSV359, a targeted alpha particle therapy for solid tumors expressing fibroblast activation protein alpha (FAP-α), a marker associated with poor prognosis in multiple cancers.

• Perspective Therapeutics has dosed the first patient in a new cohort of its Phase 1/2a trial evaluating VMT01 in combination with Bristol Myers Squibb's nivolumab (Opdivo) for melanoma patients with positive MC1R imaging scans. • Initial results from earlier monotherapy cohorts presented at the Society for Melanoma Research showed a promising safety profile with no dose-limiting toxicities and early signs of anti-tumor activity in heavily pretreated patients. • Researchers believe VMT01's dual mechanism of action as a targeted alpha-particle therapy may enhance outcomes when combined with immune checkpoint inhibitors for patients with advanced melanoma.

Perspective Therapeutics reported encouraging interim results from its Phase 1/2a trial of \[212Pb\]VMT-α-NET in patients with advanced neuroendocrine tumors.

Perspective Therapeutics is moving forward with dose escalation of [212Pb]VMT-α-NET, a targeted alpha-particle therapy, following positive safety data in a Phase 1/2a trial.

The FDA has granted Fast Track designation to VMT01, a targeted alpha-particle therapy, for unresectable or metastatic melanoma expressing melanocortin 1 receptor (MC1R).